Cover Image

Empagliflozin-A New Chance for Patients with Chronic Heart Failure

The heart failure (HF) epidemic is one of the challenges that has been faced by the healthcare system worldwide for almost 25 years. With an ageing world population and a fast-paced lifestyle that promotes the development of cardiovascular disease, the number of people suffering from heart failure w...

Full description

Saved in:

Bibliographic Details
Main Authors:	Klaudia Kowalska (Author), Justyna Walczak (Author), Joanna Femlak (Author), Ewelina Młynarska (Author), Beata Franczyk (Author), Jacek Rysz (Author)
Format:	Book
Published:	MDPI AG, 2021-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
by: Klaudia Kowalska, et al.
Published: (2022)

Arterial Hypertension-Oxidative Stress and Inflammation
by: Julia Krzemińska, et al.
Published: (2022)

Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease
by: Weronika Frąk, et al.
Published: (2024)

Selenium as a Modulator of Redox Reactions in the Prevention and Treatment of Cardiovascular Diseases
by: Klaudia Leszto, et al.
Published: (2024)

Progress of patients hospitalized with acute heart failure treated with empagliflozin
by: Manuel Raya-Cruz, et al.
Published: (2024)

Are Nutraceuticals Beneficial in Chronic Kidney Disease?
by: Jacek Rysz, et al.
Published: (2021)

The Role of Oxidative Stress in Hypertension: The Insight into Antihypertensive Properties of Vitamins A, C and E
by: Ewelina Młynarska, et al.
Published: (2024)

Oxidative Stress in ESRD Patients on Dialysis and the Risk of Cardiovascular Diseases
by: Jacek Rysz, et al.
Published: (2020)

Cost-effectiveness of empagliflozin for the treatment of heart failure: a systematic review
by: Jinyu Liu, et al.
Published: (2023)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
by: Erik Håkansson, et al.
Published: (2021)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
by: Yi Tang, et al.
Published: (2022)

Clinical Efficacy and Safety of Empagliflozin in Patients with Acute Heart Failure from the First Day of Hospitalization
by: D. P. Golubovskaya, et al.
Published: (2023)

Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?
by: Beata Franczyk, et al.
Published: (2022)

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved
by: Andrew J.S. Coats, et al.
Published: (2024)

Quantitative effects of sodium-glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
by: Dong-Dong Wang, et al.
Published: (2022)

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria
by: Yixiang Xu, et al.
Published: (2023)

Glyceraldehyde derivatives inspired by empagliflozin as potential anti-heart failure agents independent of glucose-lowering effects
by: Xiao Li, et al.
Published: (2024)

Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland
by: Hallinen T, et al.
Published: (2023)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
by: Hilmi Alnsasra, et al.
Published: (2023)

Integration of RNA-Seq and Machine Learning Identifies Hub Genes for Empagliflozin Benefitable Heart Failure with Reduced Ejection Fraction
by: Yang Q, et al.
Published: (2023)

Identification of Key Immune-Related Genes in the Treatment of Heart Failure After Myocardial Infarction with Empagliflozin Based on RNA-Seq
by: Zhang P, et al.
Published: (2023)

Acceptance of the disease by patients over 70 with chronic heart failure
by: Danuta Sternal, et al.
Published: (2023)

Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia
by: Siew Chin Ong, et al.
Published: (2023)

Effects of Empagliflozin on Gut Microbiota in Heart Failure with a Preserved Ejection Fraction: The Design of a Pragmatic Randomized, Open-Label Controlled Trial (EMPAGUM)
by: Guan XQ, et al.
Published: (2023)

Combination of Empagliflozin and Liraglutide protects heart against isoproterenol-induced myocardial infarction in rats
by: Neng Fisheri Kurniati, et al.
Published: (2023)

Comorbid conditions in patients with chronic heart failure (according to the registry of chronic heart failure in the Tyumen region)
by: Anna A. Airapetian, et al.
Published: (2023)

Chance Encounters, Transformation, and New Beginnings
by: Marybeth Lima
Published: (2022)

THE "NEW" DRUG CLASSES IN THE TREATMENT OF CHRONIC HEART FAILURE AND THEIR EVIDENCE BASE
by: S. N. Tereshchenko, et al.
Published: (2015)

THE "NEW" DRUG CLASSES IN THE TREATMENT OF CHRONIC HEART FAILURE AND THEIR EVIDENCE BASE
by: S. N. Tereshchenko, et al.
Published: (2015)

Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy
by: Colbert GB, et al.
Published: (2023)

Ivabradine in Chronic Heart Failure
by: Hadeer Eid, et al.
Published: (2020)

Hyperkalemia in chronic heart failure
by: Hakan Altay
Published: (2021)

Acceptance of the disease by patients with heart failure
by: Małgorzata Fraś, et al.
Published: (2024)

Itch in Patients with Acute Heart Failure
by: Malgorzata Ponikowska, et al.
Published: (2019)

Immunological changes in patients with chronic heart failure
by: Olga Malgazdarova, et al.
Published: (2018)

Cardiorenal syndrome in patients with chronic heart failure
by: L. A. Kovalevskaya, et al.
Published: (2015)

Clinical features of the course of chronic heart failure with a new coronavirus infection
by: Victoria V. Streltsova, et al.
Published: (2023)

Empagliflozin improves chronic hypercortisolism-induced abnormal myocardial structure and cardiac function in mice
by: Qing-Qing Zhang, et al.
Published: (2020)

Osoba starsza a kryzys we współczesnej rodzinie w ujęciu systemowym
by: Ewelina Franczyk
Published: (2021)

Impact of cognitive function on compliance with treatment in heart failure
by: Beata Jankowska-Polańska, et al.
Published: (2017)